These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 25323222)
1. Inhibition of autophagy potentiates the efficacy of Gli inhibitor GANT-61 in MYCN-amplified neuroblastoma cells. Wang J; Gu S; Huang J; Chen S; Zhang Z; Xu M BMC Cancer; 2014 Oct; 14():768. PubMed ID: 25323222 [TBL] [Abstract][Full Text] [Related]
2. The protective autophagy activated by GANT-61 in MYCN amplified neuroblastoma cells is mediated by PERK. Wang J; Huang S; Tian R; Chen J; Gao H; Xie C; Shan Y; Zhang Z; Gu S; Xu M Oncotarget; 2018 Mar; 9(18):14413-14427. PubMed ID: 29581853 [TBL] [Abstract][Full Text] [Related]
3. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma. Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175 [TBL] [Abstract][Full Text] [Related]
4. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase. Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881 [TBL] [Abstract][Full Text] [Related]
5. Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo. Wickström M; Dyberg C; Shimokawa T; Milosevic J; Baryawno N; Fuskevåg OM; Larsson R; Kogner P; Zaphiropoulos PG; Johnsen JI Int J Cancer; 2013 Apr; 132(7):1516-24. PubMed ID: 22949014 [TBL] [Abstract][Full Text] [Related]
6. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma. Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342 [TBL] [Abstract][Full Text] [Related]
7. The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells. Gu L; Chu P; Lingeman R; McDaniel H; Kechichian S; Hickey RJ; Liu Z; Yuan YC; Sandoval JA; Fields GB; Malkas LH EBioMedicine; 2015 Dec; 2(12):1923-31. PubMed ID: 26844271 [TBL] [Abstract][Full Text] [Related]
8. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas. Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720 [TBL] [Abstract][Full Text] [Related]
9. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865 [TBL] [Abstract][Full Text] [Related]
10. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma. Lovén J; Zinin N; Wahlström T; Müller I; Brodin P; Fredlund E; Ribacke U; Pivarcsi A; Påhlman S; Henriksson M Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1553-8. PubMed ID: 20080637 [TBL] [Abstract][Full Text] [Related]
11. Druggable epigenetic suppression of interferon-induced chemokine expression linked to Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720 [TBL] [Abstract][Full Text] [Related]
12. Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells. Paffhausen T; Schwab M; Westermann F Cancer Lett; 2007 May; 250(1):17-24. PubMed ID: 17141950 [TBL] [Abstract][Full Text] [Related]
13. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification. Liu X; Mazanek P; Dam V; Wang Q; Zhao H; Guo R; Jagannathan J; Cnaan A; Maris JM; Hogarty MD Oncogene; 2008 Feb; 27(10):1478-88. PubMed ID: 17724465 [TBL] [Abstract][Full Text] [Related]
14. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Molenaar JJ; Ebus ME; Geerts D; Koster J; Lamers F; Valentijn LJ; Westerhout EM; Versteeg R; Caron HN Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12968-73. PubMed ID: 19525400 [TBL] [Abstract][Full Text] [Related]
15. Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification. Nara K; Kusafuka T; Yoneda A; Oue T; Sangkhathat S; Fukuzawa M Int J Oncol; 2007 May; 30(5):1189-96. PubMed ID: 17390021 [TBL] [Abstract][Full Text] [Related]
16. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma. Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931 [TBL] [Abstract][Full Text] [Related]
17. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Rounbehler RJ; Li W; Hall MA; Yang C; Fallahi M; Cleveland JL Cancer Res; 2009 Jan; 69(2):547-53. PubMed ID: 19147568 [TBL] [Abstract][Full Text] [Related]
18. MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma. Agarwal P; Glowacka A; Mahmoud L; Bazzar W; Larsson LG; Alzrigat M Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175848 [TBL] [Abstract][Full Text] [Related]
19. MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells. Cortés C; Kozma SC; Tauler A; Ambrosio S Cell Oncol (Dordr); 2015 Oct; 38(5):341-52. PubMed ID: 26306783 [TBL] [Abstract][Full Text] [Related]